Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ophthalmic panel tackles Prelex technique

This article was originally published in The Gray Sheet

Executive Summary

Study criteria for intraocular lenses to correct presbyopia following clear lens extraction will be explored March 5 by FDA's Ophthalmic Devices Panel in Gaithersburg, Md. Potential candidates for a presbyopic lens exchange (Prelex) indication include Advanced Medical Optics' Array multifocal lens, Eyeonics' CrystaLens AT-45 and Alcon's Acrysof multifocal IOL. Array has been available for U.S. use in cataract surgery since 1997, while AT-45 earned approval Nov. 14 for aphakic treatment of near, immediate and distance vision (1"The Gray Sheet" Dec. 22, 2003, p. 25)...

You may also be interested in...

CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling

Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts